Saroj Velamakanni, Fahy Gurteen: the Discovery, Development & Clinical Validation of Cancer BioMarkers.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Saroj Velamakanni, Fahy Gurteen: the Discovery, Development & Clinical Validation of Cancer BioMarkers.
Released on: August 26, 2015. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Fahy Gurteen is a small Irish backed, UK registered and Cambridge based in-vitro cancer diagnostics company with some interesting IP.
  • Summary
  • Transcript
  • Participants
  • Company
Fahy Gurteen is a small Irish backed, UK registered and Cambridge based in-vitro cancer diagnostics company with some interesting IP. Saroj Velamakanni talks with Adrian Dawkes about how their novel technologies can be cost effectively used across multiple indications of cancer in clinical studies such as Breast, Ovarian and Lung cancer, to develop patient stratification. Their technologies can also be applied in early stage research in the development of biomarkers for the detection, prognosis and treatment of cancer, and in the development of liquid biopsy based biomarkers.
Saroj Velamakanni, Principal Scientist and Research Director at Fahy Gurteen UK Limited
Saroj Velamakanni, Principal Scientist and Research Director at Fahy Gurteen UK Limited
Fahy Gurteen